Triple-Negative Breast Cancer (TNBC) Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02393794Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Treatment